Patents by Inventor Chong Hak CHAE

Chong Hak CHAE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220249482
    Abstract: The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.
    Type: Application
    Filed: February 18, 2022
    Publication date: August 11, 2022
    Inventors: Kwangho Lee, Inji Shin, Gildon Choi, Chong Hak Chae, Hyeon Jeong Choe, Myoung Eun Jung, Byeong Uk Jeon, Byoung Chul Cho, Chae Won Park, Hwan Kim, Krishna Babu Duggirala
  • Patent number: 11365215
    Abstract: Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: June 21, 2022
    Assignees: Korea Research Institute of Chemical Technology, Research & Business Foundation Sungkyunkwan University
    Inventors: Kwangho Lee, Sang Dal Rhee, Gildon Choi, Imran Ali, Chong Hak Chae, Moon Kook Jeon, Seok Hee Park, Youn Sook Lee
  • Patent number: 11253516
    Abstract: The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: February 22, 2022
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Kwangho Lee, Inji Shin, Gildon Choi, Chong Hak Chae, Hyeon Jeong Choe, Myoung Eun Jung, Byeong Uk Jeon, Byoung Chul Cho, Chae Won Park, Hwan Kim, Krishna Babu Duggirala
  • Publication number: 20200179384
    Abstract: The present invention relates to a N2,N4-diphenylpyrimidin-2,4-diamine derivative, a method for preparing the same, and a pharmaceutical composition for the prevention or treatment of cancer, containing the same as an active ingredient. The derivative shows a relatively weak EGFR activity inhibitory effect on wild-type EGFR, a high inhibitory ability on EGFR mutation, and a high inhibitory ability on even FLT3 and FLT3 mutation, and thus, can be effectively used for the treatment of cancer with EGFR mutation or cancer with FLT3 or a mutation thereof, and the derivative shows a synergy effect at the time of combination administration, and thus can be effectively used for the treatment of combination administration.
    Type: Application
    Filed: December 6, 2018
    Publication date: June 11, 2020
    Inventors: Kwangho Lee, Inji Shin, Gildon Choi, Chong Hak Chae, Hyeon Jeong Choe, Myoung Eun Jung, Byeong Uk Jeon, Byoung Chul Cho, Chae Won Park, Hwan Kim, Krishna Babu Duggirala
  • Patent number: 10369149
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: August 6, 2019
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon Hwang, Hyoung Rae Kim, Jae Du Ha, Sung Yun Cho, Hee Jung Jung, Pilho Kim, Chang Soo Yun, Chong Ock Lee, Chi Hoon Park, Chong Hak Chae, Sunjoo Ahn
  • Patent number: 10100019
    Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: October 16, 2018
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Pilho Kim, Hyoung Rae Kim, Sung Yun Cho, Jae Du Ha, Hee Jung Jung, Chang Soo Yun, Jong Yeon Hwang, Chi Hoon Park, Chong Ock Lee, Sunjoo Ahn, Chong Hak Chae
  • Patent number: 10053458
    Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: August 21, 2018
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Chang Soo Yun, Hyoung Rae Kim, Sung Yun Cho, Hee Jung Jung, Kwangho Lee, Chong Hak Chae, Chong Ock Lee, Chi Hoon Park, Pilho Kim, Jong Yeon Hwang, Jae Du Ha, Sun Joo Ahn
  • Publication number: 20180208625
    Abstract: Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.
    Type: Application
    Filed: March 14, 2018
    Publication date: July 26, 2018
    Inventors: Kwangho Lee, Sang Dal Rhee, Gildon Choi, Imran Ali, Chong Hak Chae, Moon Kook Jeon, Seok Hee Park, Youn Sook Lee
  • Publication number: 20180111905
    Abstract: The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: April 6, 2016
    Publication date: April 26, 2018
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Pilho Kim, Hyoung Rae Kim, Sung Yun Cho, Jae Du Ha, Hee Jung Jung, Chang Soo Yun, Jong Yeon Hwang, Chi Hoon Park, Chong Ock Lee, Sunjoo Ahn, Chong Hak Chae
  • Publication number: 20180104242
    Abstract: The present invention relates to a 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The 4-(2-amino-tetrahydronaphthaleneyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.
    Type: Application
    Filed: December 30, 2015
    Publication date: April 19, 2018
    Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Jong Yeon HWANG, Hyoung Rae KIM, Jae Du HA, Sung Yun CHO, Hee Jung JUNG, Pilho KIM, Chang Soo YUN, Chong Ock LEE, Chi Hoon PARK, Chong Hak CHAE, Sunjoo AHN
  • Publication number: 20170145007
    Abstract: The present invention relates to a pyrimidine-2,4-diamine derivative or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition for prevention or treatment of cancer comprising the same as an effective ingredient. A compound according to the present invention has the good effect of inhibiting anaplastic lymphoma kinase (ALK) activity, whereby a therapeutic effect on cancer cells having an anaplastic lymphoma kinase (ALK) fusion protein such as EML4-ALK, NPM-ALK, etc. can be enhanced and it is expected that a recurrence of cancer will be effectively inhibited. As such, the compound can be effectively used in a pharmaceutical composition for prevention or treatment of cancer.
    Type: Application
    Filed: May 21, 2015
    Publication date: May 25, 2017
    Inventors: Chang Soo YUN, Hyoung Rae KIM, Sung Yun CHO, Hee Jung JUNG, Kwangho LEE, Chong Hak CHAE, Chong Ock LEE, Chi Hoon PARK, Pilho KIM, Jong Yeon HWANG, Jae DU HA, Sun Joo AHN
  • Publication number: 20170008924
    Abstract: Pyrrolidine carboxamido derivatives, optical isomers thereof, and salts thereof that are able to prevent, improve, and/or treat inflammatory conditions, including inflammatory bowel disease, and methods for preparing and using the same are provided.
    Type: Application
    Filed: July 8, 2016
    Publication date: January 12, 2017
    Inventors: Kwangho Lee, Sang Dal Rhee, Gildon Choi, Imran Ali, Chong Hak Chae, Moon Kook Jeon, Seok Hee Park, Youn Sook Lee
  • Patent number: 9199944
    Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: December 1, 2015
    Assignee: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
    Inventors: Kwangho Lee, Hyoung Rae Kim, Chi Hoon Park, Chong Ock Lee, Jong Kook Lee, Hee Jung Jung, Sung Yun Cho, Chong Hak Chae, Sang Un Choi, Jae Du Ha
  • Publication number: 20150152069
    Abstract: Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers.
    Type: Application
    Filed: February 9, 2015
    Publication date: June 4, 2015
    Inventors: Kwangho LEE, Hyoung Rae KIM, Chi Hoon PARK, Chong Ock LEE, Jong Kook LEE, Hee Jung JUNG, Sung Yun CHO, Chong Hak CHAE, Sang Un CHOI, Jae Du HA